Newsfilter article unlocker

So my name is Masha Poyorovsky. I am a scientist at P&V Pharmaceuticals. We are a company that's developing Rosetta POP for the treatment of women with platinum resistant refractory ovarian cancer. So I have dedicated my life to basically trying to develop drugs that target p53 directly. So, I think the biggest takeaway from the talk today was to give people a background on Rosatipop, that it is a lengthy drug discovery, drug development, it's a lengthy process. It starts with very, very basic science and the idea that yes, we are only targeting one specific missense mutation in p53 but we are able to take this protein that doesn't work and make it into a functional tumor suppressor not only does it function but it's actually able to reduce tumor burden in patients which is the cleanest and first validation of the fact that p53 can be restored and it can have positive clinical outcome and so today what my presentation really focused on is how did we get from an idea that p53 could be targeted which is something that Arnie Levine had 13 years ago to today in 2026 being a year away from FDA approval for this drug and what data supported us moving it into the clinic, how we convinced ourselves that it works, and why only one mutant at the time. It is a eye-opening and humbling experience. I am so honored to be able to come here and to meet patients. I'm not a clinician. I have spent my entire academic career in the lab. The conferences that I go to are populated by other scientists, and even though we are fully guided by trying to affect patients' lives, we don't ever get to really interact with patients directly, and so to have this much energy directed at us and the idea that is real humans that we could give hope to with our drugs. It really is a wonderful experience and I am so grateful to LFSA for bringing me here and allowing me this opportunity to actually interact with patients and to give maybe a tiny little bit of hope to the community as well. So this is a question that we wrestle with all the time at PMV and these are continuous conversations that we're having because Rosetta Pop is a year away from being approved by the FDA. I am certain that it will be available for patients very soon, but yes, we are very focused in my work we're incredibly focused on trying to address other mutations and how can we help more patients with p53 mutations and treat tumors that arise in those patients and i think the next steps and they are a little bit challenging would be to find agents that are able to target more than one mutation at a time so maybe not all the mutations because and I talked about this in my presentation, they are very different. But there are classes of mutations, and so I think we will be able to, as a next evolution of B53 therapeutics, will be agents that can treat multiple B53 mutations at the same time. And maybe they're not going to restore function the way Rosatapop does, but just being able to find the cells that have mutant P53 and disrupt those cells might be an interesting therapeutic approach. So we are very focused on, in our basic research and our drug development strategies, on targeting more mutants, other mutants. we're moving past this Y220C variant to hopefully help other patients, more patients. Awareness is key, absolutely. So our population is quite small, the Y2 20C population that could benefit from the drug. And so outside of big academic centers like MD Anderson, letting community oncologists know that the drug exists, even, that there are ongoing clinical trials that could benefit for patients. And I know you guys are already advocating for broad screening for P53 mutations for patients that have cancer. That will also help us identify future patients. So anything you can do to draw attention The fact that this therapy is out there, it exists, would really help both patients and us kind of draw more patients into our trials as well as more patients once the drug is approved and it's available for people. Now we could certainly use people knowing more about the existence of this therapy because even though it seems, especially in this setting, genetic screening is so prevalent. There are still many, many places that are diagnosing tumors just on the histology alone. Genetic screening is not a part of the initial diagnosis, and these patients may go into very harsh treatments at their first line, whereas they have an option now, at least, for something that could be much less punishing as a therapy and could also have an effect. I think for families with LFS, I hope we can get risatapone as a therapy that could be given to as a prophylactic. And I think that's a very tangible goal, actually. It's not a pie-in-the-sky kind of idea. I think it could very well be something that at least for the subset of patients could be a pre-treatment as opposed to simply continuous screening, that there would be something that they can take to delay onset. That's my hope for, most immediate hope for Zetapop and the LFS patients.